However, further studies in a larger population sample using multiple serum markers are necessary to confirm our current data before serum CEA and Cyfra21-1 can be used clinically as a tumor biomarker for the risk of high radon exposure-induced LC. The gene discussed is CEACAM5; the disease is neoplasm.